Business Description
ImmunityBio Inc
NAICS : 541714
SIC : 8731
ISIN : US45256X1037
Share Class Description:
IBRX: Ordinary SharesTotal Employee Number:
691Description
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | -1.35 | |||||
Debt-to-Equity | -0.83 | |||||
Debt-to-EBITDA | -0.99 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.62 | |||||
Beneish M-Score | -0.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 397.3 | |||||
3-Year EBITDA Growth Rate | 34.9 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 32.5 | |||||
3-Year Book Growth Rate | 22.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 128.56 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.77 | |||||
9-Day RSI | 47.09 | |||||
14-Day RSI | 51.28 | |||||
3-1 Month Momentum % | -4.12 | |||||
6-1 Month Momentum % | 199.57 | |||||
12-1 Month Momentum % | 143.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.67 | |||||
Quick Ratio | 6.66 | |||||
Cash Ratio | 5.61 | |||||
Days Inventory | 1818.66 | |||||
Days Sales Outstanding | 81.3 | |||||
Days Payable | 3510.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.9 | |||||
Shareholder Yield % | -4.89 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.34 | |||||
Operating Margin % | -185.41 | |||||
Net Margin % | -606.15 | |||||
EBITDA Margin % | -515.19 | |||||
FCF Margin % | -212.31 | |||||
OCF Margin % | -208.82 | |||||
ROA % | -180.03 | |||||
ROIC % | -117.26 | |||||
3-Year ROIIC % | -21.13 | |||||
ROC (Joel Greenblatt) % | -433.23 | |||||
ROCE % | -177.88 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 56.3 | |||||
EV-to-EBIT | -12.05 | |||||
EV-to-Forward-EBIT | -42.53 | |||||
EV-to-EBITDA | -12.32 | |||||
EV-to-Revenue | 63.47 | |||||
EV-to-Forward-Revenue | 38.24 | |||||
EV-to-FCF | -29.9 | |||||
Price-to-GF-Value | 0.19 | |||||
Earnings Yield (Greenblatt) % | -8.3 | |||||
FCF Yield % | -3.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IBRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmunityBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 140.977 | ||
| EPS (TTM) ($) | -0.85 | ||
| Beta | 0.0635 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 2.15 | ||
| Volatility % | 224.36 | ||
| 14-Day RSI | 51.28 | ||
| 14-Day ATR ($) | 0.607996 | ||
| 20-Day SMA ($) | 8.053815 | ||
| 12-1 Month Momentum % | 143.21 | ||
| 52-Week Range ($) | 1.95 - 12.43 | ||
| Shares Outstanding (Mil) | 1,047.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmunityBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmunityBio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 13 days | ||
| General meeting for 2026 | 2026-06-09 10:30 | 7.17 (+0.70%) | ||
| Guidance call for 2026 | 2026-06-08 | 6.92 (-3.22%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 8.38 (+8.83%) | ||
| Annual report for 2025 | 2026-02-23 | 8.70 (+0.81%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-23 | 8.70 (+0.81%) | ||
| Guidance call for 2025 | 2025-12-02 | 2.30 (-3.97%) | ||
| Guidance call for 2025 | 2025-11-06 | 2.15 (-1.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 2.08 (-5.88%) |
Show
Entries
ImmunityBio Inc Frequently Asked Questions
What is ImmunityBio Inc(IBRX)'s stock price today?
The current price of IBRX is $8.23. The 52 week high of IBRX is $12.43 and 52 week low is $1.95.
When is next earnings date of ImmunityBio Inc(IBRX)?
The next earnings date of ImmunityBio Inc(IBRX) is 2026-07-24 Est..
Does ImmunityBio Inc(IBRX) pay dividends? If so, how much?
ImmunityBio Inc(IBRX) does not pay dividend.
Guru Commentaries on NAS:IBRX
No articles.
Press Release
Articles on ImmunityBio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers